CS logo
small CS logo
Instituto de Infectologia Emilio Ribas

Sao Paulo, Brazil
Specialized hospital in São Paulo, State of São Paulo
Av. Dr. Arnaldo, 165 - Pacaembu, São Paulo - SP, 01246-900

About Instituto de Infectologia Emilio Ribas


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
National Institute of Allergy and Infectious Diseases (NIAID)
6
Janssen Vaccines & Prevention B.V.
3
Bristol-Myers Squibb
2
Boehringer Ingelheim
1
Butantan Institute
1
EMD Serono Research & Development Institute, Inc.
1
Evandro Chagas National Institute of Infectious Disease
1
Gilead Sciences
1
Hoffmann-La Roche
1
Janssen Research & Development, LLC
1
Pfizer
1
Total Rows: 16

Clinical Trials at Instituto de Infectologia Emilio Ribas


During the past decade, Instituto de Infectologia Emilio Ribas conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 6 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 3 clinical trials were completed. i.e. 30% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years1100000011882211110011000000Started TrialsCompleted Trails20152016201720182019202020210510
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
2000-03-01
2008-11-01
Completed
4,150
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
2000-06-01
2002-04-01
Completed
730
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
2001-02-01
2003-09-01
Completed
Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
2004-01-01
2009-06-01
Completed
371
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.
2004-02-01
Terminated
562
Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy
2006-06-01
2013-12-01
Completed
87
Effects of Anti-HIV Therapy on Nervous System Function
2005-03-01
2007-07-01
Completed
297
Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents
2007-09-17
2017-05-18
Completed
153

Rows per page:

1–24 of 24

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Instituto de Infectologia Emilio Ribas" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 6 trials, followed by "Janssen Vaccines & Prevention B.V." with 3 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored and "Butantan Institute" with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Infectologia Emilio Ribas" #1 collaborator was "Gilead Sciences" with 2 trials as a collaborator, "Chiron Corporation" with 1 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 1 trials as a collaborator, "Federal University of Minas Gerais" with 1 trials as a collaborator and "Fundação de Amparo à Pesquisa do Estado de São Paulo" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.
Created with Highcharts 11.1.0Top Leading SponsorsNational Institute ofAllergy and InfectiousDiseases (NIAID): 6National Institute ofAllergy and InfectiousDiseases (NIAID): 6Janssen Vaccines &Prevention B.V.: 3Janssen Vaccines &Prevention B.V.: 3Bristol-Myers Squibb: 2Bristol-Myers Squibb: 2Boehringer Ingelheim: 1Boehringer Ingelheim: 1Butantan Institute: 1Butantan Institute: 1EMD Serono Research &Development Institute,Inc.: 1EMD Serono Research &Development Institute,Inc.: 1Evandro ChagasNational Institute ofInfectious Disease: 1Evandro ChagasNational Institute ofInfectious Disease: 1Gilead Sciences: 1Gilead Sciences: 1Hoffmann-La Roche: 1Hoffmann-La Roche: 1Janssen Research &Development, LLC: 1Janssen Research &Development, LLC: 1

Created with Highcharts 11.1.0Top CollaboratorsGilead Sciences: 2Gilead Sciences: 2Chiron Corporation: 1Chiron Corporation: 1Eunice Kennedy ShriverNational Institute ofChild Health and HumanDevelopment (NICHD): 1Eunice Kennedy ShriverNational Institute ofChild Health and HumanDevelopment (NICHD): 1Federal University ofMinas Gerais: 1Federal University ofMinas Gerais: 1Fundação de Amparo àPesquisa do Estado deSão Paulo: 1Fundação de Amparo àPesquisa do Estado deSão Paulo: 1Gaffree & GuinleUniversitary Hospital: 1Gaffree & GuinleUniversitary Hospital: 1Hospital Couto Maia/SES/BA: 1Hospital Couto Maia/SES/BA: 1Hospital EstadualSumaré Dr. LeandroFrancheschini: 1Hospital EstadualSumaré Dr. LeandroFrancheschini: 1Hospital Nossa Senhorada Conceicao: 1Hospital Nossa Senhorada Conceicao: 1Hospital Regional deSão José - Dr. Homerode Miranda Gomes: 1Hospital Regional deSão José - Dr. Homerode Miranda Gomes: 1

Clinical Trials Conditions at Instituto de Infectologia Emilio Ribas


According to Clinical.Site data, the most researched conditions in "Instituto de Infectologia Emilio Ribas" are "HIV Infections" (9 trials), "COVID-19" (4 trials), "Hepatitis B" (2 trials), "Acute Respiratory Infection" (1 trials) and "COVID-19 Pneumonia" (1 trials). Many other conditions were trialed in "Instituto de Infectologia Emilio Ribas" in a lesser frequency.

Clinical Trials Intervention Types at Instituto de Infectologia Emilio Ribas


Most popular intervention types in "Instituto de Infectologia Emilio Ribas" are "Drug" (15 trials), "Biological" (5 trials), "Other" (4 trials), "Diagnostic Test" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (9 trials), "Ad26.COV2.S" (2 trials), "Ad26.Mos4.HIV" (1 trials), "Adefovir" (1 trials) and "Adsorbed COVID-19 (inactivated) Vaccine" (1 trials). Other intervention names were less common.

Clinical Trials Genders at Instituto de Infectologia Emilio Ribas


The vast majority of trials in "Instituto de Infectologia Emilio Ribas" are 24 trials for "All" genders.

Clinical Trials Status at Instituto de Infectologia Emilio Ribas


Currently, there are NaN active trials in "Instituto de Infectologia Emilio Ribas". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Instituto de Infectologia Emilio Ribas, undefined suspended trials, and 3 terminated clinical trials to date.
Out of the total trials that were conducted in Instituto de Infectologia Emilio Ribas, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 15Phase 3: 15Phase 2: 6Phase 2: 6Early Phase 1: 1Early Phase 1: 1Phase 1: 1Phase 1: 1Phase 4: 1Phase 4: 1

Created with Highcharts 11.1.0Trials StatusCompleted: 12Completed: 12Active, not recruiting: 5Active, not recruiting: 5Terminated: 3Terminated: 3Recruiting: 2Recruiting: 2Unknown status: 2Unknown status: 2